沙利度胺治疗可降低骨髓增生异常综合征患者骨髓细胞的凋亡水平。
Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes.
作者信息
Invernizzi Rosangela, Travaglino Erica, De Amici Mara, Brugnatelli Silvia, Ramajoli Isabella, Rovati Bianca, Benatti Chiara, Ascari Edoardo
机构信息
Internal Medicine and Medical Oncology, University of Pavia, IRCCS Policlinico S. Matteo, Pavia, Italy.
出版信息
Leuk Res. 2005 Jun;29(6):641-7. doi: 10.1016/j.leukres.2004.11.008. Epub 2005 Jan 19.
We treated with thalidomide seven patients with primary MDS and observed reduction of the transfusion requirement in three cases and reduction of bone marrow blasts in one case. The apoptotic rate of bone marrow cells diminished significantly from a mean of 43.8% to a mean of 17.5%, whereas the proliferative activity did not change. Plasma TNF-alpha, bFGF, IL-1beta levels decreased variably, whereas VEGF levels tended to increase. Matrix metalloproteinases 2 and 9 expression decreased in bone marrow cells of responders. A reduction of CD4 cells and an increase of NK cells was observed in the peripheral blood. Thus, thalidomide may produce a fairly good hematological improvement in erythroid series in MDS, with complex biological mechanisms.
我们用沙利度胺治疗了7例原发性骨髓增生异常综合征患者，观察到3例患者输血需求减少，1例患者骨髓原始细胞减少。骨髓细胞凋亡率从平均43.8%显著降至平均17.5%，而增殖活性未改变。血浆肿瘤坏死因子-α、碱性成纤维细胞生长因子、白细胞介素-1β水平有不同程度下降，而血管内皮生长因子水平有升高趋势。反应者骨髓细胞中基质金属蛋白酶2和9的表达下降。外周血中观察到CD4细胞减少和自然杀伤细胞增加。因此，沙利度胺可能通过复杂的生物学机制在骨髓增生异常综合征的红系中产生相当好的血液学改善。
Zotero 插件